Review article: Towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 5, 2004, Pages 40-47

  Armstrong, D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ESOPHAGEAL COLUMNAR METAPLASIA; ESOPHAGUS CARCINOMA; GASTROINTESTINAL ENDOSCOPY; HISTOLOGY; HUMAN; INTESTINE METAPLASIA; PRIORITY JOURNAL; STOMACH MUCOSA;

EID: 7044229271     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02132.x     Document Type: Conference Paper

References (38)

1. Winters C, Spurling TJ, Chobanian SI, et al. Barrett's esoph-II agus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
2. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
3. Malfertheiner P, Leodolter A, Vieth M, et al. Which Factors Have an Impact on Healing and Symptom Relief in Patients with Erosive and Non-Erosive GERD Treated with Esomeprazole? An Analysis Based on the ProGERD Study Initiative. Gastroenterology 2002; 122 (4) (Suppl. 1): A198 (abstract S1283).
4. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
5. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
6. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
7. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
8. Richter JE, Kahrilas PJ, Johanson J, et al. and Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-5.
9. Lauritsen K, Deviere J, Bigard MA, et al. and the Metropole Study Group. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41.
10. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus Am J Gastroenterol 2002; 97: 1888-95.
11. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033-6.
12. Reynolds JC, Rahimi P, Hirschl D. Barrett's esophagus: clinical characteristics. Gastroenterol Clin N Am 2002; 31: 441-9.
13. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-85.
14. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short-segment of Barrett's esophagus. Dig Dis Sci 1992; 37: 143-7.
15. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344: 1533-6.
16. Nandurkar S, Talley NJ, Martin CJ, Ng TH, Adams S. Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut 1997; 40: 710-5.
17. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett's) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-8.
18. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
19. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-94.
20. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-9.
21. Wallner B, Sylvan A, Stenling R, Janunger KG. The esophageal Z-line appearance correlates to the prevalence of intestinal metaplasia. Scand J Gastroenterol 2000; 35: 17-22.
22. Wallner B, Sylvan A, Janunger KG. Endoscopic assessment of the 'Z-line' (squamocolumnar junction) appearance: reproducibility of the ZAP classification among endoscopists. Gastrointest Endosc 2002; 55: 65-9.
23. Ofman JJ, Shaheen NJ, Desai AA, Moody B, Bozymski EM, Weinstein WM. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am J Gastroenterol 2001; 96: 876-81.
24. Haggitt RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
25. Hayward J. The lower end of the esophagus. Thorax 1961; 16: 36-41.
26. Gottfried MR, McClave SA, Boyce HW. Incomplete intestinal metaplasia in the diagnosis of columnar-lined esophagus (Barrett's esophagus). Am J Clin Pathol 1989; 92: 741-6.
27. McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc 1987; 33: 413-6.
28. Bombeck CT, Dillard DH, Nyhus LM. Muscular anatomy of the gastroesophageal junction and role of phrenoesophageal ligament. Ann Surg 1966; 164: 643-54.
29. Hassall E. Barrett's esophagus: new definition and approach in children. J Pediatr Gastroenterol Nutr 1993; 16: 345-64.
30. Hoshihara Y. Complications of gastroesophageal reflux disease. 2. Endoscopic diagnosis of Barrett esophagus - can Barrett esophagus be diagnosed by endoscopic observation alone? [Translated] Nippon Naika Gakkai Zasshi [J Jpn Soc Int Med] 2000; 89: 85-90.
31. Takubo K, Sasajima K, Yamashita K, Tanaka Y, Fujita K. Double muscularis mucosae in Barrett's esophagus. Hum Pathol 1991; 22: 1158-61.
32. Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 2002; 97: 554-60.
33. Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001; 136: 1267-73.
34. Weston AP, Badr AS, Hassannein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999; 94: 3420-6.
35. Eisen G, Montgomery EA, Azumi N, et al. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials. Gastrointest Endosc 1999; 50: 814-8.
36. Armstrong D, Monnier P, Nicolet M, et al. Endoscopic assessment of oesophagitis. Gullet 1991; 1: 63-7.
37. Kim R, Rose S, Shar AO, Weiner M, Reynolds JC. Extent of Barrett's metaplasia: a prospective study of the serial change in the area of Barrett's measured by quantitative endoscopic imaging. Gastrointest Endosc 1997; 45: 456-62.
38. Levine DS, Blount PL, Rudolph RE, et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol 2000; 95: 1152-7.